Weekly Anesthesiology Research Analysis
This week in anesthesiology featured high-impact evidence synthesis and pragmatic randomized trials that influence perioperative practice. A large meta-analysis in Anesthesiology found modern hydroxyethyl starch solutions do not increase AKI in surgical patients, challenging prior regulatory caution. A randomized trial showed low‑dose preoperative olanzapine (5 mg) improves patient-reported recovery and reduces postdischarge nausea after ambulatory surgery. An ECT anesthetic RCT demonstrated rem
Summary
This week in anesthesiology featured high-impact evidence synthesis and pragmatic randomized trials that influence perioperative practice. A large meta-analysis in Anesthesiology found modern hydroxyethyl starch solutions do not increase AKI in surgical patients, challenging prior regulatory caution. A randomized trial showed low‑dose preoperative olanzapine (5 mg) improves patient-reported recovery and reduces postdischarge nausea after ambulatory surgery. An ECT anesthetic RCT demonstrated remimazolam produces superior seizure quality versus propofol, informing agent choice where seizure adequacy matters.
Selected Articles
1. Hydroxyethyl Starch and Perioperative Complications: a Systematic Review and Meta-analysis.
Pooling 114 trials (13,951 patients), this meta-analysis found modern HES solutions (130/0.4–0.42), when used mainly for <24 hours in surgical settings, did not increase acute kidney injury (RR 1.02) nor worsen perioperative creatinine change; no meaningful increases in adverse events or mortality were seen.
Impact: Directly addresses regulatory concerns by providing large-scale, contemporary synthesis that challenges the assumed renal harm of modern HES in surgical patients and may influence perioperative fluid policies.
Clinical Implications: In selected surgical patients (non‑critically ill) and when limited to short-term use (<24 h), modern HES can be considered as an option within goal-directed fluid therapy, though avoidance in sepsis/critically ill populations remains advised.
Key Findings
- Meta-analysis of 114 trials (13,951 patients) found no increase in AKI risk with HES 130/0.4–0.42 (RR 1.02 [0.91–1.16]).
- Perioperative creatinine change was non-inferior; trial sequential analysis supported adequate information size.
- No meaningful increase in adverse events or mortality; most trials limited HES to <24 hours.
2. Preoperative Olanzapine and Quality of Recovery after Ambulatory Surgery: A Randomized Clinical Trial.
In a randomized, double-blind trial of 384 ambulatory female patients, preoperative oral olanzapine 5 mg improved QoR-40 scores on postoperative day 1 by 9.0 points and day 2 by 4.8 points versus placebo, and significantly reduced odds of any and severe nausea on POD1 without prolonging PACU stay.
Impact: A large, well-conducted RCT showing a low-dose antipsychotic improves patient-centered recovery metrics and reduces PDNV; immediately actionable for ambulatory anesthesia protocols.
Clinical Implications: Consider adding 5 mg olanzapine to multimodal antiemetic regimens (with counseling about sedation) for ambulatory patients at risk of PDNV; further validation across sexes/ages is advisable.
Key Findings
- QoR-40 improved on POD1 by 9.0 points (95% CI 6.1–11.8) and POD2 by 4.8 points (95% CI 2.0–7.6).
- Odds of any nausea on POD1 decreased (OR 0.43) and severe nausea decreased (OR 0.26).
- PACU length of stay unchanged; benefits robust after multiplicity correction.
3. Seizure adequacy and safety of remimazolam in electroconvulsive therapy for patients with psychiatric disorders: a double-blind randomized crossover trial.
In a double-blind randomized crossover trial of 56 patients (284 ECT sessions), remimazolam (0.2 mg/kg) produced significantly longer EEG and EMG seizure durations and higher seizure energy indices than propofol, indicating improved seizure adequacy; clinicians should monitor for post-ictal cardiovascular hyperdynamic states.
Impact: First rigorous randomized evaluation of remimazolam for ECT demonstrating superior seizure quality versus propofol, directly informing anesthetic agent choice in ECT practice.
Clinical Implications: Remimazolam can be considered when optimizing seizure quality in ECT, with protocols to anticipate and manage possible post‑ictal hypertension/tachycardia.
Key Findings
- EEG seizure duration: 37.0 s (remimazolam) vs 18.5 s (propofol); p < 0.001.
- EMG seizure duration and seizure energy index were also significantly greater with remimazolam.
- Post-ictal cardiovascular hyperdynamic states observed as a safety consideration.